Kornimate/medical-research-clean huggingface dataset:
aerobic exercise and covid-19 survivors with post-intensive care syndrome (pics)

Conditions: COVID-19; Post Intensive Care Syndrome

Summary: to investigate the effects of aerobic exercise program on physical activity, aerobic capacity, anxiety\& depression in covid-19 survivors discharged from intensive care unit. there is evidence in the literature that post-intensive case survivors who have been mechanically ventilated will likely experience short- and medium-term consequences in the form of post intensive care syndrome (pics).

the notion that patients surviving intensive care and mechanical ventilation for several weeks can be discharged home without further medical attention is a dangerous illusion. post-intensive care syndrome and other severe conditions will require not only adequate screening but early rehabilitation and other interventions. so, this focused control trial will contribute particularly to determining the effects of the aerobic exercise program in covid-19 survivors with post-intensive care syndrome.

Eligibility criteria:
inclusion criteria: * patients undergo mechanical ventilation in the icu. * recovered from covid-19 \& discharged from icu within the past 2 months. * hospital anxiety and depression scale (hads)\>8. * scale≥ 2 on mrc dyspnoea scale. * subjects consenting to participate in the study. exclusion criteria: * positive covid-19 test. * copd and other respiratory diseases. * pre-existing psychotic dementia-type illness. * acute neurologic diseases (meningitis, ischemic hemorrhagic stroke). * patients with chronic systemic disease.

Keywords: aerobic exercise covid-19 survivors post intensive care syndrome
compare the clinical efficacy of prototype toothpastes.

Conditions: Gingival Diseases

Summary: evaluate clinical efficacy of a prototype toothpaste on control of dental plaque gingival inflammation


Eligibility criteria:
inclusion criteria: * male or female volunteers 18-65 years of age * good general health * must sign informed consent form * minimum of 16 natural uncrowned teeth (excluding third molars) must be present. * no history of allergy to personal care consumer products, or their ingredients, * relevant to any ingredient in the test products as determined by the dental/medical * professional monitoring the study. * dental selection criteria: average full mouth gi score should be in the range of * - 2.0. heavy plaque formers should be avoided. target a full mouth pi * (quigley-hein) to be in the range of 1.5-3.0 * if of child bearing potential and on birth control (diaphragm, birth control pills, * birth control implants, iud (intrauterine device), condoms) exclusion criteria: * subjects unable or unwilling to sign the informed consent form. * medical condition which requires pre-medication prior to dental visits/procedures * moderate or advanced periodontal disease * 2 or more decayed untreated dental sites at screening. * other disease of the hard or soft oral tissues. * impaired salivary function (e.g. sjogren's syndrome or head and neck irradiation). * use of medications that are currently affect salivary flow. * use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1. * pregnant or nursing women. * participation in any other clinical study within 1 week prior to enrollment into this * study. * use of tobacco products * subjects who must receive dental treatment during the study dates. * current use of antibiotics for any purpose. * history of allergy to common dentifrice ingredients * presence of an orthodontic appliance which interferes with plaque scoring. * history of allergy to natural remedies, such as herbal ingredients * immune compromised individuals (hiv, aids, immuno suppressive drug therapy) * smoker
randomized clinical trial of three drug combinations for late-stage gambiense human african trypanosomiasis

Conditions: Trypanosomiasis, African

Summary: the treatment human african trypanosomiasis (hat) in the meningoencephalitic phase relies on two molecules officially registered: melarsoprol, the most commonly used, has a poor safety profile and is becoming ineffective due to parasite resistance; and eflornithine, with better tolerance but more complicated and expensive to implement in endemic countries. nifurtimox, registered only for chagas' disease but used off-label since the 1970's in series of cases of hat, is at present the only other available alternative. the very limited number of compounds available, the lack of prospects for the development of new products and the emergence of resistance are arguments for the use of therapeutic combinations. this study evaluates the efficacy and safety of three drug combination therapies: melarsoprol-nifurtimox, melarsoprol-eflornithine and eflornithine-nifurtimox.

dosages per drug are the same in either arm of the study: iv melarsoprol 1.8 mg/kg/day, daily for 10 days; iv eflornithine 400 mg/kg/day, 6-hourly for 7 days; oral nifurtimox 15 or 20 (children \<15 years) mg/kg/day, 8-hourly for 10 days. for efficacy assessment, patients are followed-up for 24 months after treatment, with planned clinical and laboratory controls. the safety assessment includes clinical and hematological adverse events.

Eligibility criteria:
inclusion criteria: * confirmed second-stage t.b. gambiense infection : * infection diagnosed parasitologically (blood or lymph node fluid) and white blood cells \> 5/mm3 in cerebrospinal fluid (csf) * or trypanosomes detected in the csf with any csf cell count * and resident in the district * and written consent of the patient or of one of the parents/guardians for children under 15 years of age. exclusion criteria: * trypanosome absent from blood (or lymph node fluid) and from csf * or women pregnant on inclusion * or previous history of hat confirmed treated during the last 24 months * or impossibility of regular access to the treatment centre during the 2 years following the end of the treatment * or less than 10 kg of body weight * or refugee patient

Keywords: trypanosomiasis gambiense combination drug therapy sleeping sickness uganda
vaccine therapy for patients with stage iii melanoma

Conditions: Malignant Melanoma

Summary: this is a phase 3 study in patients with melanoma that has spread to the lymph nodes (stage iii), and who have had all of their cancer surgically removed. the purpose of this study is to evaluate the ability of the cancervax™ vaccine to prevent or slow the recurrence of melanoma.


Eligibility criteria:
* must have stage iii melanoma * must have had all clinically-detectable disease surgically removed * cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. some corticosteroids, and certain types of radiation therapy) * cannot have hiv or hepatitis a, b, or c
mindfulness based resilience training

Conditions: Stress, Psychological

Summary: the investigators aim to evaluate the mindfulness based resilience training (mbrt) intervention for mayo clinic employees in order to provide evidence for improved ability to cope with stress and decreased work-related burnout and stress-related symptoms as a result of mbrt training. in addition, the investigators aim to compare the effects of mbrt + smartphone sleep feedback, a smartphone resilience intervention + smartphone sleep feedback, or waitlist control +smartphone sleep feedback in a randomized clinical trial in a sample of 75 mayo clinic employees.

the investigators aim to compare the effects of mbrt + smartphone sleep feedback, a smartphone resilience intervention + smartphone sleep feedback, or waitlist control +smartphone sleep feedback in a randomized clinical trial in a sample of 75 mayo clinic employees. specific self-report outcomes include: well-being, stress, anxiety, depression, fatigue, resilience, self-compassion, and burn-out, assessed at pre-, post- and 3-month followup. objective outcomes, derived from smartphone-driven self-monitoring, include sleep quality and emotional experiencing, assessed throughout the six-week intervention period. the investigators will explore whether changes in objectively measured sleep quality and emotional experiencing will mediate treatment effects on self-report outcomes. the investigators will also explore whether treatment effects are more robust in self-selected versus randomized groups by drawing on the investigators' existing data.

Eligibility criteria:
inclusion: 1. stress subscale of the dass-21 needs to be a score 5 or greater and 2. must have a smart phone, and 3. ability to attend at least 5 complete sessions. exclusion : 1. stress subscale of the dass-21 less than 5. 2. must have a smart phone.

Keywords: well-being stress resilience self-compassion
titan trial: reducing phantom limb pain in people with amputations

Conditions: Phantom Limb Pain; Amputation

Summary: the goal of this clinical trial is to investigate the effectiveness of two rehabilitation programs for individuals who have undergone amputations and are experiencing phantom limb pain. the main question it aims to answer is: - in individuals who have undergone amputations and are experiencing phantom limb pain, what is the effectiveness of a progressive rehabilitation program compared to a treatment program consisting of transcutaneous electrical nerve stimulation and cranial electrical stimulation on reducing pain intensity and pain interference? a total of 208 participants will be randomized into two groups: progressive rehabilitation program and stimulation devices. the progressive rehabilitation program includes pain science education, sensory training, and left/right judgements, imagined movements and mirror therapy. the treatment program for the group receiving the stimulation devices includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. both interventions will be delivered via eight, up to 1-hour telehealth sessions. outcome measures will be assessed at baseline and weeks 12, 24 and 52.


Eligibility criteria:
inclusion criteria: * experiencing phantom limb pain for at least three months. * report at least one episode of phantom limb pain in the previous week. * report at least 4 points in pain intensity over the previous 7 days, assessed using the 11-point numerical pain rating scale. * be a resident in australia for the intervention and follow-up period. * have access to the internet and smart device (e.g., mobile phone). * be proficient in english. exclusion criteria: * bilateral amputation. * scheduled for major surgery during the study period. * pain in the intact limb. * vision impairment that would preclude successful participation. * auditory impairment that would preclude successful participation. * cognitive problems that would preclude effective participation in trial procedures (e.g., alzheimer's, dementia). * previously diagnosed neurological disorders that affect the movement of the intact limb (e.g., stroke, parkinson, multiple sclerosis). * completed graded motor imagery in the order of left/right judgements, imagined movements, and mirror therapy. * have contraindications for the use of stimulation devices (e.g., pacemaker, spinal cord stimulator).
clinical validation study in allergic conjunctivitis to birch pollen during allergen challenge in alyatec eec

Conditions: Allergic Conjunctivitis

Summary: this is a single center open study designed to determine the concentration of airborne birch pollen inducing an allergic conjunctivitis response in individuals allergic to birch pollen, during allergen exposures in the alyatec environmental exposure chamber (eec).


Eligibility criteria:
inclusion criteria: * subjects having signed the informed consent * subjects affiliated to a social security scheme * subjects with birch pollen rhinitis and conjunctivitis with: * a history of rhinoconjunctivitis for at least the last 2 consecutive pollen seasons. * a positive skin prick-test to birch (wheal diameter \>6 mm compared to the negative control), * specific immunoglobulin e (ige) for birch\> 0.1 kiu/l * women of childbearing potential must have a negative pregnancy test during the entire study period with an effective means of contraception: oral contraceptives, intrauterine device, condom with spermicide for at least one month before inclusion in the study and for the duration of the study. at each study visit and each exposure on d1, a urine pregnancy test will be performed. * a positive conjunctival provocation test to birch during the screening visit at a dilution of 100ir/ml maximum exclusion criteria: * known asthmatic subjects allergic to birch pollen * use of oral corticosteroids in the 4 weeks preceding inclusion in the study * use of biotherapy in the 4 months preceding inclusion in the study * desensitization to birch pollen in the last 5 years * uncontrolled chronic pathologies (hypertension, cardiac, respiratory, renal pathology). * active autoimmune disease * uncontrolled systemic hypertension * subjects who participated in another clinical study in the three months prior to inclusion * pregnancy and breast feeding * inability to understand and act upon the information provided

Keywords: allergy conjunctivitis
fruquintinib plus pd-1 in refractory mss metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: the survival of the refractory crc is dismal and therapy options are limited ，the researchers aim to investigate the efficacy, safety, and predictors of fruquintinib plus pd-1 in refractory mss metastatic colorectal cancer in a real-world setting.

the invesgators conducted a retrospective single arm, single-center study in which patients with mss/pmmr mcrc were received fruquintinib combined with anti-pd-1 antibodies after progressed at least two lines of standard chemotherapy with or without targeted drugs such as bevacizumab and cetuximab at the hunan cancer hospital from 1th january 2019 to 30th june 2022. eligible patients were aged 18 years or older and had histologically or cytologically confirmed adenocarcinoma of the colon or rectum; with patients who have at least one non-resectable measurable lesion to evaluate by response evaluation criteria in solid tumors (recist version 1.1).the primary endpoint was overall survival (os).

Eligibility criteria:
inclusion criteria: 1. patients with mss/pmmr mcrc who have been received fruquintinib combined with anti-pd-1 antibodies after progressed at least two lines of standard chemotherapy with or without targeted drugs such as bevacizumab and cetuximab at the hunan cancer hospital from 1th january 2019 to 30th june 2022; 2. eligible patients were aged 18 years or older 3. had histologically or cytologically confirmed adenocarcinoma of the colon or rectum; 4. patients who have at least one non-resectable measurable lesion to evaluate by response evaluation criteria in solid tumors (recist version 1.1). 5. an eastern cooperative oncology group performance status of 0-2; exclusion criteria: 1. pregnancy, lactating female or possibility of becoming pregnant during the study. 2. has not recovered from clinically relevant non-hematologic ctcae grade ≥ 3 toxicity of previous anticancer therapy (excluding alopecia, and skin pigmentation). 3. has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control cns disease. 4. has severe or uncontrolled active acute or chronic infection. 5.known carriers of hiv antibodies. 6.confirmed uncontrolled arterial hypertension or uncontrolled or symptomatic arrhythmia.

Keywords: fruquintinib pd-1 pmmr/mss
ventilator strategies in icu patients with covid-19 - a national-wide retrospective observational study.

Conditions: ARDS Due to COVID-19

Summary: mechanical ventilation is likely lifesaving in patients with coronavirus disease 2019 (covid-19) but may also result in adverse events. only few studies describe the strategies used and adverse effect of mechanical ventilation in an unselected population of icu patients with covid-19. this study is designed to be a retrospective study focusing on all mechanical ventilated icu patients with covid-19 included in the national danish covid icu database between 10.03.2020 - 02.04.2021 i.e. a total of 1,193 patients. the investigators will register the use of the core interventions around mechanical ventilation and its potential adverse event, including barotrauma and prolonged ventilation. this study will provide important data on the ventilation strategies used and its potential adverse events in unselected icu patients with covid-19 and thereby inform clinicians, patients, policy-makers, and future research in this area.


Eligibility criteria:
inclusion criteria: all mechanical ventilated patients registered in the national danish covid icu database between 10.03.2020 - 02.04.2021 i.e. 1. admitted to an icu in denmark 2. laboratory-confirmed sars-cov-2 infection 3. use of invasive mechanical ventilation (ventilation via a cuffed endotracheal tube) at any time during the icu stay exclusion criteria: none

Keywords: ards mechanical ventilation covid-19
expanded access to provide gl-onc1 for the treatment of advanced cancers with no standard of care

Conditions: Advanced Stage Cancer (Solid Tumor Disease for 4 Patients); Acute Myeloid Leukemia (6 Patients)

Summary: gl-onc1 expanded access is for patients who are ineligible for an ongoing gl-onc1 clinical trial. expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. potential patients will be evaluated individually depending on gl-onc1 product supply.


Eligibility criteria:
inclusion criteria: * diagnosis of advanced cancers with no standard of care option for treatment. * willing and able to provide written, signed informed consent. * use of adequate contraception. * negative pregnancy test. exclusion criteria: * have not recovered from severe adverse events from prior therapy. * major surgery occurred within 28 days prior to treatment. * known immune system disorders such as hiv, or active hepatitis b or c infection. * clinically significant cardiac disease (new york heart association class iii or iv). * have received prior therapy with an oncolytic virus of any type. * be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, st-246). * have known allergy to ovalbumin or other egg products. * have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.
identifying optimal buprenorphine dosing for opioid use disorder treatment and prevention of overdose

Conditions: Opioid Use Disorder

Summary: the investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). the main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment response based on use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (exploratory outcome).


Eligibility criteria:
inclusion criteria: * english-speaking * age 18 years-old or older * identified by the treating physician as having moderate to severe opioid use disorder (oud) * initiating or continuing buprenorphine for treatment of opioid use disorder * history of fentanyl use (confirmed by fentanyl positive urine drug screen (uds) at intake or if on buprenorphine maintenance treatment fentanyl plus a positive uds within the last month or self- reported ongoing fentanyl use during treatment) exclusion criteria: * previous enrollment in the trial * incarcerated or in police custody\* * pregnant * live outside of rhode island (ri) * unable to provide informed consent * allergy to buprenorphine * concomitant medication use deemed to present potential for serious medication interaction by the treating clinician \*participants that become incarcerated/or in police custody during the study will be withdrawn.
evaluating the impact of the mcmaster optimal aging portal on physical mobility outcomes

Conditions: Mobility Limitation

Summary: the mcmaster optimal aging portal (the portal) was launched in 2014 to increase public access to trustworthy health information. the portal helps readers to access evidence-based resources; identify trustworthy messages; and understand scientific findings. now the investigators want to know whether using the portal changes what people know and do to stay healthy and mobile. this project will help us to: 1. understand how middle aged and older adults (age 40+) use the portal to obtain information about maintaining and improving mobility 2. evaluate whether use of the portal results in a change in knowledge about maintaining and improving mobility, or change in lifestyle behaviours that may help maintain or improve mobility with age.

physically active lifestyles are important for health aging, but most canadians do not meet published physical activity guidelines. this may be in part due to lack of access to evidence-based information on mobility and aging, and knowledge of strategies to maintain or improve mobility with age. the mcmaster optimal aging portal (the portal) was launched in 2014 to increase public access to trustworthy health information. now the investigators want to know if easy-to-understand evidence-based messages change what people know and do to stay healthy and mobile. sequential, explanatory mixed-methods design consisting of a two-armed randomized controlled trial and a qualitative process study to explore quantitative findings in depth. consent forms and a baseline survey will be sent to all interested participants. following baseline data collection, participants will be stratified by previous portal use, and randomized to the knowledge translation (kt) intervention or control group. during the 12-week kt intervention, intervention group participants will have access to the portal and will receive mobility- focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a twitter and facebook feed; a unique hashtag will be created to identify and collate relevant mobility information. control group participants will be able to access the portal in a 'self-serve' fashion, but will not receive targeted kt strategies.

Eligibility criteria:
inclusion criteria: * english-speaking exclusion criteria: * none

Keywords: mobility aging knowledge translation physical activity